Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

  • Jones S
  • Feldmann H
  • Ströher U
 et al. 
  • 159

    Readers

    Mendeley users who have this article in their library.
  • 392

    Citations

    Citations of this article.

Abstract

Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here, we developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges. Notably, vaccine vector shedding was not detectable in the monkeys and none of the animals developed fever or other symptoms of illness associated with vaccination. The EBOV vaccine induced humoral and apparent cellular immune responses in all vaccinated monkeys, whereas the MARV vaccine induced a stronger humoral than cellular immune response. No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Steven M. Jones

  • Heinz Feldmann

  • Ute Ströher

  • Joan B. Geisbert

  • Lisa Fernando

  • Allen Grolla

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free